Use of aptamers in therapy and/or diagnosis of autoimmune diseases

US9234201B2 · kind B2 · utility

Assignees

• MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER · DE
• CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN · DE

Inventors

• Ingolf Schimke · Berlin, DE
• Annekathrin Haberland · Berlin, DE
• Gerd Wallukat · Berlin, DE

Key dates

• Filing date: Mar 2, 2012
• Grant date: Jan 12, 2016
• Expiry date: Mar 2, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.